WallStSmart

Crown Castle (CCI)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 1403% more annual revenue ($63.32B vs $4.21B). CCI leads profitability with a 25.1% profit margin vs 11.8%. CCI appears more attractively valued with a PEG of 1.50. PFE earns a higher WallStSmart Score of 55/100 (C).

CCI

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: -0.67

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCISignificantly Overvalued (-29.8%)

Margin of Safety

-29.8%

Fair Value

$66.29

Current Price

$94.49

$28.20 premium

UndervaluedFair: $66.29Overvalued
PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCI3 strengths · Avg: 9.7/10
Operating MarginProfitability
47.7%10/10

Strong operational efficiency at 47.7%

Debt/EquityHealth
-12.8610/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.1%9/10

Keeps 25 of every $100 in revenue as profit

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$145.62B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CCI4 concerns · Avg: 2.8/10
P/E RatioValuation
38.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-206.7%2/10

ROE of -206.7% — below average capital efficiency

Revenue GrowthGrowth
-4.8%2/10

Revenue declined 4.8%

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCI

The strongest argument for CCI centers on Operating Margin, Debt/Equity, Profit Margin. Profitability is solid with margins at 25.1% and operating margin at 47.7%.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CCI

The primary concerns for CCI are P/E Ratio, Piotroski F-Score, Return on Equity.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CCI profiles as a declining stock while PFE is a value play — different risk/reward profiles.

CCI carries more volatility with a beta of 0.95 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (55/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crown Castle

REAL ESTATE · REIT - SPECIALTY · USA

Crown Castle is a real estate investment trust and provider of shared communications infrastructure in the United States. Its network includes over 40,000 cell towers and nearly 80,000 route miles of fiber supporting small cells and fiber solutions. Headquartered in Houston, Texas, the company has 100 offices nationwide.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?